Empath Ventures

Xylo Bio is a drug development company focused on next-generation psychedelic-inspired therapeutics for psychiatric and neurological disorders. Through a psychedelic therapeutic platform, it aims to develop non-hallucinogenic, rapid-acting medicines that can be widely available and provide improvements over current SSRI treatments. The company seeks to rewire neural circuits and restore brain function, enabling clinicians to optimize care and expand treatment options beyond traditional antidepressants.

Aperture Therapeutics is a biotechnology company dedicated to developing novel therapies for age-related neurodegenerative diseases. It employs a distinctive drug discovery platform that leverages the genetic diversity of patients to identify new disease pathways and drug targets. Currently in the pre-clinical stage, the company operates from a lab incubator, integrating insights from neuroscience and immunology to advance its research. Aperture Therapeutics' approach centers on the significance of genetic diversity in the discovery process, aiming to create more effective treatments for neurodegeneration and neuroimmunology conditions.

Motif Neurotech specializes in developing minimally invasive bioelectronic implants for monitoring and treating severe mental illnesses, focusing initially on treatment-resistant depression. The company aims to restore hope and improve quality of life by providing personalized treatments that repair neural circuits.

TARA Mind is a company dedicated to improving mental health outcomes by closing gaps in therapeutic accessibility and affordability for high-risk individuals. It offers employers a supplemental benefit that provides safe, affordable access to life-changing mental health therapies, focusing on treatment-resistant depression.

Nue Life is a company focused on enhancing mental wellness through scientifically validated treatments. It offers an innovative therapeutic ecosystem that includes at-home ketamine therapy, an interactive companion app, and virtual aftercare programs. The application utilizes knowledge graphs and artificial intelligence to provide personalized, evidence-based therapies, assisting users in diagnosing and addressing their mental health conditions. By combining advanced technology with therapeutic practices, Nue Life aims to improve brain function, performance, and overall longevity for its users.

Motif Neurotech specializes in developing minimally invasive bioelectronic implants for monitoring and treating severe mental illnesses, focusing initially on treatment-resistant depression. The company aims to restore hope and improve quality of life by providing personalized treatments that repair neural circuits.

A digital healthcare platform offering personalized care through its clinic. It provides users with a health dashboard, action plans, curated tests, products, and protocols for advanced diagnostics and vetted therapeutics.

Xylo Bio is a drug development company focused on next-generation psychedelic-inspired therapeutics for psychiatric and neurological disorders. Through a psychedelic therapeutic platform, it aims to develop non-hallucinogenic, rapid-acting medicines that can be widely available and provide improvements over current SSRI treatments. The company seeks to rewire neural circuits and restore brain function, enabling clinicians to optimize care and expand treatment options beyond traditional antidepressants.

Pangea Botanica helps to accelerate the discovery and development of therapeutics for patients by using naturally occurring compounds and traditional remedies, while preserving ethnobotanical knowledge and ecosystems. It is a biotechnology research organisation that offers drug discovery and development services.

Freedom Biosciences develops a biotechnology platform focused on next-generation psychedelic therapeutics. The company advances ketamine-based therapies and combines neuropsychiatric drugs to create treatments for mental health and substance use disorders, including depression and PTSD, with the aim of offering more effective and safer options for patients.

Kadence Bio is a clinical-stage life sciences company developing novel therapeutics, with a focus on small molecule programs addressing sexual and mental well-being. Its lead compound KH-001 is being developed as a treatment for premature ejaculation, reflecting the company’s aim to provide additional options for patients and expand therapeutic opportunities in areas with significant unmet need.

Wavepaths, established in 2018 and based in London, specializes in developing accessible technology for psychedelic therapy. The company creates personalized soundtracks using intelligent technologies and immersive media, aiming to facilitate inner exploration and emotional reconnection during drug-free therapeutic sessions. Their offerings span the fields of information technology, healthcare, and personal health.

Beond is a provider of wellness and healing treatments that focus on using ibogaine to address anxiety and other behavioral conditions. The company aims to facilitate profound transformational change for individuals grappling with issues such as chemical dependency, substance abuse, depression, anxiety, and PTSD. By offering counseling, education, and support, Beond seeks to help clients recover from addiction and heal from trauma, enabling them to overcome their mental health challenges and improve their overall well-being.

MycroDose Therapeutics is a U.S.-based pharmaceutical company focused on developing advanced drug delivery systems that utilize psychedelic compounds for the treatment of mental health disorders and cognitive degenerative diseases. The company is actively working on two of its four core technologies, which include a psilocybin transdermal delivery system and a ketamine oral mucosa delivery system. By leveraging these innovative approaches, MycroDose Therapeutics aims to enhance the efficacy and accessibility of treatments for patients dealing with these challenging conditions.

Quantified Citizen modernizes scientific research by empowering both citizen scientists and professionals. Its platform enables easy creation and participation in studies, focusing on timely health insights.